Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Patients with AML with WT TP53 but defective TP53-mediated apoptosis have a dismal survival.

JCI insight - 9 Mar 2026

Dubois Josephine, Palmer Anthony, King Darren, Rizk Mohamed, Bedi Karan, Shedden Kerby A, Malek Sami N

Abstract excerpt

The survival of patients with acute myelogenous leukemia (AML) carrying mutations in TP53 is dismal. We report the results of a detailed characterization of responses to treatment ex vivo with the MDM2 inhibitor MI219, a p53 protein stabilizer, in AML blasts from 165 patients focusing analyses on patients with WT TP53. In total 33% of AML were absolute resistant to MDM2 inhibitor-induced apoptosis, of which 45%...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Apoptosis
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Nucleophosmin

Share to Proto-Oncogene Proteins c-mdm2

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41592087
DOI: 10.1172/jci.insight.197261
PMCID: PMC13041678

Genes

TP53
MDM2
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patients with AML with WT TP53 but defective TP53-mediated apoptosis have a dismal survival.PMID 41592087Read ↗

p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.Semantic proximity Read ↗

Breaking the guardian of the genome: TP53 dysfunction in myeloid neoplasms.Semantic proximity Read ↗

The role of TP53 in acute myeloid leukemia: Challenges and opportunitiesSemantic proximity Read ↗

TP53 Mutations in Acute Myeloid Leukemia: Still a Daunting Challenge?Semantic proximity Read ↗

Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemiaSemantic proximity Read ↗

Current State and Future Prospects of Diagnosis and Management of TP53-Mutated Myeloid Neoplasms.Semantic proximity Read ↗

Clinical and Molecular Characterization of p53-Mutated Acute Myeloid LeukemiaSemantic proximity Read ↗

TP53 in Acute Myeloid Leukemia: Molecular Aspects and Patterns of Mutation.Semantic proximity Read ↗

TP53 Mutation in Acute Myeloid Leukemia: An Old Foe RevisitedSemantic proximity Read ↗

Evaluating targeted therapies in older patients with TP53-mutated AML.Semantic proximity Read ↗

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read ↗

<i>TP53</i> mutations drive therapy resistance via post-mitochondrial caspase blockadeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.